spacer
home > ebr > winter 2001 > intrabodies - valuable tools for target validation
PUBLICATIONS
European Biopharmaceutical Review

Intrabodies - Valuable Tools for Target Validation

As more and more genomes become sequenced, the number of novel proteins with unknown function is steadily increasing. Consequently, a considerable interest exists to characterise the function of many gene products and to validate them as potential drug targets in particular disease pathways. Both gene knockout and antisense techniques are employed for this purpose, but they have their limitations. Intrabodies present an attractive alternative to modulate protein function and analyse the effects. Moreover, they can also be employed to target specific domains of the protein. However, the stability of an intrabody is often greatly impaired by the reducing intracellular conditions in the cell that prevent the formation of disulfide bridges. In this article we review a number of examples for the intracellular use of antibodies and discuss selection procedures for the identification of functional intrabodies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Kirsten E. Mundt, Business Development, ESBATech AG

Kirsten Mundt PhD is a Senior Scientist at ESBATech AG, a start-up biotechnology company based in Zurich, Switzerland. She has recently been appointed Project Manager for the company's new business development sector. Kirsten graduated from the University of Dundee, UK, with an honours degree in Biochemistry and went on to gain a PhD from the University of Lausanne in Switzerland. Kirsten's extensive research has centred on molecular biology and biochemistry, with a particular focus on oncology. Her experience has led to conference speaking and academic lecturing, and her work has been published in numerous publications within the biomedical field.
spacer
Dr Kirsten E. Mundt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KITE’S CAR T-CELL THERAPY YESCARTA® (AXICABTAGENE CILOLEUCEL) FIRST IN EUROPE TO RECEIVE POSITIVE CHMP OPINION FOR USE IN SECOND-LINE DIFFUSE LARGE B-CELL LYMPHOMA AND HIGH-GRADE B-CELL LYMPHOMA

Stockley Park, UK – 16 September, 2022 – Kite, a Gilead Company, today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, axicabtagene ciloleucel will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment. Although 60% of newly diagnosed LBCL patients will respond to their initial treatment, 40% will relapse or will not respond and need 2nd line treatment.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement